Achaogen (OTCMKTS:AKAOQ) and AEON Biopharma (NASDAQ:AEON) Financial Analysis

AEON Biopharma (NASDAQ:AEON) and Achaogen (OTCMKTS:AKAOQ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Institutional & Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. 0.9% of AEON Biopharma shares are owned by insiders. Comparatively, 7.8% of Achaogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares AEON Biopharma and Achaogen”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	$5.04	0.27
Achaogen	$8.73 million	0.14	-$186.51 million	N/A	N/A

AEON Biopharma has higher earnings, but lower revenue than Achaogen.

Profitability

This table compares AEON Biopharma and Achaogen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Achaogen	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings for AEON Biopharma and Achaogen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	1	1	1	3.00
Achaogen	0	0	0	0	0.00

Risk & Volatility

AEON Biopharma has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Comparatively, Achaogen has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500.

Summary

AEON Biopharma beats Achaogen on 6 of the 9 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Achaogen

Achaogen, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial agents for multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. On April 15, 2019, Achaogen, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 29, 2020.